Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 11/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16595830 | 0.84 | AHR (0.47) | PNMTASIC3CMA1AHRADRA2A | |
| SCHEMBL15373652 | 0.77 | PNMT (0.45) | PNMTASIC3CMA1AHRBRD4 | |
| SCHEMBL13774153 | 0.74 | HTR5A (0.41) | PARP10PARP11 | |
| SCHEMBL290721 | 0.71 | PNMT (0.48) | PNMTASIC3CMA1AHRBRD4 | |
| SCHEMBL23328978 | 0.69 | HPGD (0.38) | — | |
| SCHEMBL10289251 | 0.69 | ALDH1A1 (0.36) | ADRA2AADRA2BADRA2C | |
| SCHEMBL17858325 | 0.69 | — | — | |
| SCHEMBL3141361 | 0.69 | PNMT (0.56) | PNMTASIC3CMA1AHRBRD4 | |
| SCHEMBL14319287 | 0.69 | ALDH1A1 (0.37) | — | |
| SCHEMBL30855391 | 0.68 | BRD4 (0.56) | PNMTASIC3CMA1AHRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633750-B1 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | EISAI R&D MAN CO LTD (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20060235042-A1 | Synthesis | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1633750-A2 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | Eisai Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004078757-A2 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAIDONINES | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235042-A1 | Synthesis | AZI2, CYP3A5, CYP3A7 | PNMT 145/4885ASIC3 4561/4885CMA1 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.